Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amyloid and Tau PET Imaging in DPPOS (Metformin vs Placebo)
NCT03757910Phase 1Terminated
- Start
- Oct 2019
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of metformin in Alzheimer's disease (AD). Primary endpoints: Brain Amyloid Standardized Uptake Value Ratio at 1 hour and Brain Tau Standardized Uptake Value Ratio at 1 hour. Started Oct 2019; status: terminated.
02
Drugs
metformin
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03757910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03757910.